Keytruda pembrolizumab regulatory update

EMA’s CHMP recommended approval of Keytruda pembrolizumab from Merck as monotherapy to treat advanced melanoma. The humanized IgG4 mAb against PD-1 receptor ( PDCD1; PD-1; CD279) is marketed in the ...